Clinical Trials in New York

Showing 16161-16180 of 22,668 trials

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

NCT00854646

This is an open-label, Phase I study to determine the highest amount of the study drug, ON 01910.Na, that can be safety given to patients with high risk myelodysplastic syndromes (MDS) or refractory leukemias. Patients will receive ON 01910.Na (at a starting dose of 650 mg/m2) intravenously by 3-day continuous infusion once every 2 weeks. Successive courses will use longer infusion times and/or higher doses of the drug until toxicity, effectiveness, or ineffectiveness is recognized. In addition, the amount of drug in the blood will be measured, any antitumor activity will be documented, and the biological effect of ON 01910.Na on cell-cycle pathways will be evaluated in peripheral blood mononuclear cells.

Acute Myelocytic LeukemiaAcute Lymphocytic LeukemiaChronic Myelocytic Leukemia+2 more

Traws Pharma, Inc.22 participantsStarted Oct 2008

New York, New York, United States

COMPLETEDNA< 1 mile

A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.

NCT02210208

Part A The primary objective of Part A will be to verify performance and safety of Mepitel® Ag, a meshed, non- adherent soft silicone wound contact layer containing silver in the treatment of skin grafts in surgical burn patients. Part B The primary objective of Part B will be to examine the usefulness of Mepilex® Transfer Ag as an adequate option for donor site healing.

Burn InjurySkin Graft

Molnlycke Health Care AB25 participantsStarted Sep 2014

Phoenix, Arizona, United States • Orlando, Florida, United States • New York, New York, United States +1 more locations

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.

Find Trials by Condition in New York

Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis

Modafinil for Smoked Cocaine Self-Administration

A Safety Study of SGN-CD33A in AML Patients

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Preventing Propofol Injection Pain: Prospective Randomized Trial Comparing Propofol Versus Fospropofol

Scale-up of an Internet-Delivered Study for HIV+ Men

YM443 in Subjects With Functional Dyspepsia

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Simvastatin Therapy for Moderate and Severe COPD

Condition of Approval Study

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.